TRINITY BIOTECH PLC (TRIB) Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Medical - Specialties
Trinity Biotech plc NASDAQ:TRIB Healthcare · Medical - Specialties
Mkt Cap $5.09M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 5
Trinity Biotech’s Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure
Trinity Biotech's Trinovium subsidiary has signed a contract with Texas-based Red Team Investments to supply advanced cooling fluids and analytical systems for a U.S. commercial pilot in AI and high-performance computing data centers.
RTI, owner of the X-MDC modular data center technology, is committed as a commercial pilot customer with paid product supply, giving Trinovium real-world operating data to support product validation and broader commercialization of its direct-to-chip liquid cooling line.
The companies are targeting a data center liquid cooling market that third-party research projects to grow from roughly $4 billion in 2026 to $27 billion by 2033.
For Trinity Biotech, a commercial-stage diagnostics company, the deal marks a first commercial foothold for its diversification into AI infrastructure cooling, though no contract value or revenue terms were disclosed.
• 1mo ago AI analysis › Press Release ⚠ 2
Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
Trinity Biotech provided a business update highlighting operational improvements, including the appointment of Jordi Romero as Head of Commercial Operations for Europe and the expansion of its PrePsia patent portfolio to nine granted U.S. and European patents.
The company reported progress in its manufacturing transformation, having completed approximately 9 million TrinScreen HIV tests under an outsourced model and initiating production of Uni-Gold™ HIV tests.
Despite commercial progress, the company received a staff determination letter from Nasdaq confirming it failed to regain compliance with the minimum $15 million market value of publicly held shares requirement by the August 18 deadline.
Management intends to request a hearing before a Nasdaq panel to automatically stay any suspension, expressing confidence that pending strategic transactions will restore compliance before the February 2027 extension deadline.
• 2mo ago AI analysis › Press Release
Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure
Trinity Biotech’s subsidiary Trinovium has entered a strategic collaboration with Echelon Data Centres to develop liquid cooling solutions for AI and high-density computing infrastructure.
The partnership aims to combine Trinovium’s fluid manufacturing capabilities with Echelon’s hyperscale data center expertise, targeting a market projected to grow from $4 billion to $27 billion by 2033.
Echelon brings significant scale to the agreement, currently developing over 700 MW of capacity with 1.4 GW secured across Europe.
• 2mo ago AI analysis › Press Release ⚠ 1
Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
Trinity Biotech secured $7.0 million in additional investment from Perceptive Advisors, comprising $2.5 million in new debt and $4.5 million in capitalized interest, to support strategic initiatives including its CGM+ and Trinovium businesses.
The company regained compliance with Nasdaq’s minimum bid price requirement after its shares closed at $1.00 or higher for ten consecutive business days ending August 6, 2026.
Preliminary revenue for the second quarter was approximately $10.5 million, broadly consistent with the prior quarter, as the company continues its operational transformation.
• 2mo ago AI analysis › Press Release
Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
Trinity Biotech entered a strategic collaboration with Latch Medical to combine its CGM+ wearable biosensor platform with Latch's intradermal drug delivery technology.
The partnership aims to evaluate the development of precision therapeutic solutions for metabolic conditions like diabetes and obesity by using real-time metabolic data to guide drug delivery.
Trinity Biotech agreed in principle to make a strategic equity investment in Latch Medical, with support from its largest investor Perceptive Advisors.
• 3mo ago AI analysis › Press Release ● Major ⚠ 2
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
Trinity Biotech announced a 1-for-30 reverse split of its American Depositary Shares (ADSs), effective at the open of trading on July 24, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
The ratio change modifies the ADS representation from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares, with The Bank of New York Mellon acting as the depositary.
No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold for cash, with net proceeds distributed to holders.
• 3mo ago AI analysis › Press Release
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
Trinity Biotech announced results from a pre-pivotal clinical trial showing its CGM+ platform can successfully distinguish between true blood glucose lows and false lows caused by nocturnal sensor compression.
The analysis of over 5,000 hours of wear data validates the multi-sensor architecture's ability to provide physiological context, addressing a common limitation in the $15 billion global CGM market.
Management believes this differentiation supports the commercial opportunity and partner relevance as the solution advances toward pivotal trial and regulatory submission.
• 4mo ago AI analysis › Press Release
Trinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling
Trinity Biotech’s Trinovium subsidiary secured Silver Membership in the Open Compute Project, marking a key validation step for its entry into the AI data center liquid cooling market.
The membership provides a platform to engage with hyperscale operators and contribute to next-generation cooling standards, potentially accelerating product validation and adoption.
Third-party analysis cited in the release projects the data center liquid cooling market will grow from $4 billion in 2026 to $27 billion by 2033, representing a 31.5% CAGR.
• 4mo ago AI analysis › Press Release ⚠ 1
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
Trinity Biotech has terminated its Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., an affiliate of Yorkville Advisors Global.
The company stated it does not intend to utilize the equity line facility further, a move that reflects its current financing strategy and removes a potential source of dilution.
Trinity Biotech remains focused on human diagnostics and diabetes management, recently expanding into wearable biosensors and AI data center cooling through acquisitions.
• 4mo ago AI analysis › Press Release ● Major
Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market
Trinity Biotech announced the launch of Trinovium, a new subsidiary focused on healthcare-grade fluid technology for AI data center liquid cooling, leveraging its existing high-purity manufacturing capabilities.
The company targets a market projected to grow from $4 billion in 2026 to $27 billion by 2033, driven by the transition from air to liquid cooling for high-density AI workloads.
This initiative aims to utilize existing US and EU production capacity to enter the market capital-efficiently while maintaining focus on its core diagnostics portfolio.
• 4mo ago AI analysis › Press Release ● Major
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
Trinity Biotech secured purchase orders for over 2 million units of its TrinScreen HIV rapid test, scheduled for delivery in Q3 2026, which supports full-year revenue and profitability targets.
Q1 2026 revenue increased 43% year-over-year to $10.8 million, driven by a $3.3 million contribution from Rapid HIV sales and growth in haemoglobin products.
The company reported significant operational leverage with gross margin expanding to 35.4% from 25.2%, reducing the net loss to $4.4 million compared to $8.8 million in the prior year.
• 4mo ago AI analysis › Press Release ● Major
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
globenewswire.com • 6mo ago 
